TOKYO -- Analysts are split on the outlook for Japanese drugmaker Eisai's new Alzheimer's treatment, with questions remaining over how many hospitals will have the diagnostic capabilities needed to administer it.
Pharmaceuticals
Eisai's new Alzheimer's drug divides market watchers
Leqembi's price point spurs optimism after Aduhelm, but wide use unclear
The success of Leqembi, developed by Eisai and Biogen, depends on the availability of tests needed for its prescription and other factors. (Photo courtesy of Eisai)
Read Next
.jpg?width=700&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=394)
Latest on Pharmaceuticals
